Objectives. To define the specificity and positive predictive value of anti-b 2 -glycoprotein 1 (anti-b 2 GP1) antibodies for the diagnosis of antiphospholipid syndrome (APS).
Antiphospholipid antibodies are a heterogeneous family of autoantibodies and include antibodies directed against cardiolipin (aCL) or other phospholipids, detected by enzyme-linked immunosorbent assay (ELISA), and lupus anticoagulant (LAC), detected by clotting tests. These antibodies are associated with the clinical manifestations of venous or arterial thrombosis and recurrent foetal losses. The association of one clinical criterion with one biological criterion (aCL anduor LAC on two or more occasions at least 6 weeks apart) defines the antiphospholipid syndrome (APS) w1x. APS can be primary or secondary, when it occurs in patients with other autoimmune diseases, particularly systemic lupus erythematosus. aPL antibodies can also be found in other clinical circumstances, such as infections, malignancies and sometimes in healthy subjects.
It is now known that aPL antibodies are directed not only against phospholipids but also against a complex of a phospholipid with one of a group of phospholipidbinding plasma proteins (cofactors), such as b 2 -glycoprotein 1 (b 2 GP1) w2, 3x and prothrombin w4x, and that antibodies directed against these cofactors can be detected by ELISA in the absence of phospholipids w5, 6x. Many reports demonstrate the association of antib 2 GP1 antibodies with the APS w6, 7-11x and some reports show that anti-b 2 -GP1 antibodies can be found alone without aPL antibodies w12, 13x.
The aim of our study was (i) to define the specificity and positive predictive value (PPV) of anti-b 2 GP1 antibodies for the diagnosis of APS in a large population without prior knowledge of aCL status and to compare them with the specificity and PPV of aCL antibodies, and (ii) to investigate whether anti-b 2 GP1 antibodies may be found in the absence of aCL and establish whether searching for them in the absence of aCL is helpful in the diagnosis of APS.
Materials and methods

Patients
We selected sera from 191 consecutive patients (from the departments of internal medicine and gynaecology and the thrombosis unit) that had been sent to the laboratory for routine aPL determination. We searched for aCL immunoglobulin (Ig) G and IgM and anti-b 2 GP1 IgG and IgM. Sera were collected by venipuncture and stored at 2208C in aliquots until use. Medical records of the study subjects were reviewed retrospectively by one physician without prior knowledge of the biological data. The clinical criteria for the diagnosis of APS were as follows: vascular thrombosis (venous or arterial) or pregnancy morbidity (one or more unexplained deaths beyond the 10th week of gestation; one or more premature births because of severe pre-eclampsia or severe placental insufficiency; three or more unexplained consecutive spontaneous abortions before the 10th week of gestation). Clinical and biological data were then recorded. A definitive diagnosis of APS was made when at least one clinical and one biological criterion was present. A positive biological criterion was confirmed at least 6 weeks later.
Methods aCL IgG and IgM were detected separately using commercial kits (Kallestad; Chaska, MN, USA). The negative cut-off was established at < 10 U GPL and < 10 U MPL; values >15 were considered positive and values between 10 and 15 were considered doubtful.
Anti-b 2 GP1 antibodies were detected with an inhouse ELISA using b 2 GP1 from Diagnostica Stago (Asnières, France). The assay was validated with sera proposed for the European APL Forum for b 2 GP1 ELISA Standardization w14x. Briefly, microplates (Maxisorp; Nunc, Roskilde, Denmark) were coated overnight with 5 mguml of b 2 GP1. The plates were then blocked with gelatin. After washing, 1 : 50 diluted sera wserum samples from the patients, a pool of normal human sera as negative control, an aliquot of a positive serum as positive control (from one positive patient) and a pool of five positive sera (made by mixing several positive sera) used to produce a standard curve)x were incubated on coated and uncoated wells in duplicate for 1 h at 208C. After washing, human serum antibodies were detected using an alkaline phosphatase-conjugated goat anti-human IgG (heavy and light chain) (Bioatlantic, Nantes, France), and if a positive result was obtained, the serum was also tested with an alkaline phosphatase conjugated goat anti-human IgG and IgM separately (c or m specific) (Sigma, St Louis, MO). After addition of pNPP (Sigma), optical density (OD) was measured at 405 nm. Results were expressed in semiquantitative units (negative, doubtful, low positive, positive) with respect to the standard curve after subtracting the OD of uncoated wells from the OD of coated wells. The cut-off value was defined as the mean + 2 S. 
Results
We studied 191 sera (from 87 patients from the department of internal medicine, 27 from the department of gynaecology and 77 from the thrombosis unit). Seven patients were diagnosed as having primary or secondary APS and the 184 remaining patients were diagnosed as having other diseases.
aCL antibodies
Of the 191 patients, 36 were aCL-positive (cut-off 10 U GPL or U MPL) (Table 1A) . Thirteen were confirmed in tests on a second serum. Seven were the patients diagnosed as having APS (aCL positivity was confirmed for all seven patients) and 29 were diagnosed as having other diseases. The specificity of aCL for the diagnosis of APS was 84% and the PPV was 19% (Table 2A) . If we chose a cut-off of 15 U GPL or U MPL, 22 sera were aCL-positive (Table 1B) . Eleven were confirmed in tests on a second serum. The seven APS patients were still positive. Fifteen were diagnosed as having other diseases, giving a specificity for diagnosis of APS of 92% and a PPV of 32% (Table 2B) .
Anti-b 2 GP1 antibodies
Twelve patients were anti-b 2 GP1-positive (doubtful, low positive or positive). All except one were confirmed by heavy-chain specific anti-Ig ELISA. Seven were aCLpositive and had clinical manifestations of APS. Five were in the group that had other diseases; three of these were aCL-positive (cut-off 10 U GPL or U MPL) ( Table 1) value was 15 U GPL or U MPL. Two of these five patients were aCL-negative and anti-b 2 GP1-positive; none of the five had clinical manifestations related to APS. The patient who was doubtful for anti-b 2 GP1 and had a high level of aCL antibodies was a 25-yr-old woman. Doubtful anti-b 2 GP1 antibodies were found in this patient on several occasions. She had an aPL determination after her first pregnancy, which stopped spontaneously after 5 weeks of gestation. She had no lupus anticoagulant and no history of thrombosis. Her next pregnancy was conducted under aspirin (100 mg) treatment from conception until 35 weeks of gestation and was successful. For anti-b 2 GP1 antibodies, specificity for the diagnosis of APS among the population tested regardless of aCL status was 97% and PPV was 58% (Table 2 ). In the population of aCL-positive patients (cut-off at 10 U GPL or U MPL), specificity was 90% and PPV 70%.
With a cut-off of 15 U GPL or U MPL, one patient had anti-b 2 GP1 antibodies with aCL and no clinical manifestations. The PPV was 87% in aCL-positive patients and specificity 93% ( Table 2 ).
Discussion
Previous reports have shown that anti-b 2 GP1 antibodies are closely correlated with aCL in APS and that they are not usually present in other circumstances in which aCL can be found (e.g. infections). Different authors have reported various associations: anti-b 2 GP1 IgG and thrombosis w6, 15x, anti-b 2 GP1 IgM w16x or IgG w17x and obstetric complications. In the present study, all seven APS patients were positive for anti-b 2 GP1. Nevertheless, the sensitivity and negative predictive value of anti-b 2 GP1 antibodies for the diagnosis of APS cannot be calculated because of the small number of APS patients in our series. This study shows that antib 2 GP1 antibodies have a higher specificity for the diagnosis of APS than aCL and, more importantly, a better PPV. We conclude that screening for anti-b 2 GP1 antibodies in aCL-positive patients increases the specificity and the PPV of testing for aCL. The sensitivity of anti-b 2 GP1 antibodies in APS needs to be determined before we can substitute this test for aCL testing. Testing for anti-b 2 GP1 in aCL-positive patients could identify high-risk patients and allow the physician to propose prophylactic treatment with regard to vascular thrombosis or obstetric complications.
Some reports have described patients with antibodies directed against b 2 GP1 but no detectable antibodies against phospholipids in standard assays, raising the question of testing systematically for anti-b 2 GP1 antibodies when APS is suspected. A recent study in patients with recurrent abortion or failure of implantation after in vitro fertilization concluded that screening for antib 2 GP1 antibodies without aPL was not warranted w18x. In another recent study, testing for anti-b 2 GP1 did not identify additional patients who were negative for aCL with either recurrent spontaneous abortion or unexplained foetal death. The authors concluded that there were no data to support routine testing for anti-b 2 GP1 in addition to testing for aPL antibodies in these patients w19x.
We tested 191 sera from 191 patients for both antibodies (aCL and anti-b 2 GP1 antibodies) and found 12 anti-b 2 GP1-positive sera. Seven were aCL-positive and had clinical features of APS. Four were antib 2 GP1-positive with no or very little aCL detectable. All four patients were free of clinical signs of APS. One patient had doubtful anti-b 2 GP1 antibodies and a high level of aCL antibodies. She was placed in the category of other diseases because she had no clinical criteria of APS w1x. However, to prevent obstetric complications she was treated with aspirin during her second pregnancy. APS might have developed in the absence of prophylactic treatment (e.g. pre-eclampsia or foetal growth retardation). We conclude that there is no need to screen for anti-b 2 GP1 antibodies in the absence of aCL antibodies and in the absence of a strong clinical suspicion of APS.
